Aktiechat - investeringstips

	12/8 15:00 af investor1989	Okay. thats great. You said this morning in the radio that arzerra competition in europe was hard because Ibrutinib was giving out for free. Can you clarify that ?
	12/8 15:00 af Jan Van de Winkel	and of course, encouraging early clinical data for HuMax-TF-ADC, as well as another set of strong financial results.
	12/8 14:59 af Jan Van de Winkel	...and entered a commercial agreement with BioNTech in the field of immuno oncology for DuoBody.
	12/8 14:59 af Jan Van de Winkel	...achieved a USD 10 Mn for dara progress in Phase 3, positive results for a Phase 3 in relapsed CLL for ofa....
	12/8 14:58 af Jan Van de Winkel	Certainly - the filing of the BLA for daratumumab mono therapy, two regulatory submissions for ofatumumab....
	12/8 14:57 af investor1989	Can you start with giving us an update on the most important Developments in the Q2 ?
	12/8 14:57 af investor1989	Great. Nice to have you back here
	12/8 14:56 af Jan Van de Winkel	I am here with David Eatwell, Genmab's CFO, and looking forward to this Q & A.
	12/8 14:51 af investor1989	This session starts in about 10 minutes